Cipla Q1 FY26 Earnings Call Analysis

1. Financial Summary:

• Consolidated Revenue: INR6,957 crores, up 4% YoY.
• EBITDA: Margin of 25.6%, broadly flat YoY.
• PAT: INR1,298 crores, up 10.2% YoY, representing 18.7% of sales.
• Gross Margin: 68.8%, an increase of 156 basis points Y-o-Y.
• R&D Investment: INR432 crores, 6.2% of revenue.
• ETR: 27%, same as YoY.
• Net Cash: INR10,379 crores.

2. Geographic Revenue Breakdown:

• US Business:
  • Revenue of $226 million.
  • Albuterol ranked #1 with 19.5% market share.
  • Lanreotide matched last year's average quarterly sales.
  • Launched Nano Paclitaxel and Nilotinib.
  • Signed agreement to launch a biosimilar in Q2 FY26 (Filgrastim).
  • Preparing for generic Advair, Symbicort, and other inhalation assets launches.
  • Supply diversification: 1/3 from US facilities, India operations, and strategic partners.
  • China facility fully utilized.
  • Commentary: Adjusting to price erosion in older, larger products (Revlimid), balanced by new launches. Expects peptide launches and respiratory pipeline to cushion Revlimid impact.
• India (Domestic Formulations):
  • 6% growth YoY, breaching INR3,000 crores.
  • 44% of global revenue.
  • Branded prescription business skewed towards respiratory and anti-infective therapies.
  • Launched Voltido Trio Ciphaler.
  • Chronic segment: 61.5% share of total sales.
  • 5 new brands added to the INR100 crores club, totaling 29.
  • Leads in 6 therapies with top 5 rankings in IPM.
  • Trade generics business delivered strong growth.
  • Consumer Health business: Nicotex, Omnigel, and Cipladine securing #1 positions.
  • Commentary: Respiratory and acute segments grew at 4-5%, impacting overall growth. Expects strong respiratory growth for the full year.
• One Africa:
  • 11% YoY growth in USD terms.
  • South Africa grew 6% in ZAR terms.
  • Private market secondary growth of 5.6%.
• EMEU:
  • 8% revenue growth in USD terms.
  • Driven by DTM and B2B segments.
  • Maintained margin stability by leveraging internal assets.

3. R&D and Pipeline:

• R&D Expenses: 6.2% of revenue (INR432 crores).
• Key Pipeline Products:
  • Generic Advair (H2 launch expected).
  • Generic Symbicort.
  • Peptide assets (2-3 launches this year).
  • Biosimilars (Filgrastim launch in Q2 FY26 through partnership).
  • GLP-1 (Semaglutide) - Aiming for first wave of launches.
• Biosimilar Strategy: In-licensing assets in the near term, own biosimilar assets by '29-'30. Committed upwards of $100 million to the joint venture for biosimilar development.

4. Regulatory & Plant Updates:

• Medispray (Kundaim, Goa): US FDA inspection classified as VAI (in Q4 FY24, result in Q1 FY26).
• Sitec Labs (Navi Mumbai): US FDA inspection classified as VAI.
• Indore Facility: Reinspection expected within the 2-year period.

5. Guidance, Outlook & Targets:

• Management Commentary:
  • US Generics Pricing: Expects peptide launches and respiratory pipeline to cushion Revlimid impact.
  • Domestic Growth: Confident of growing in line with the industry for the next 3 quarters.
  • R&D Strategy: Focus on GLP-1 category, aiming to be among the first wave of launches.

Metric	Target Value	Timeframe
EBITDA Margin	23.5% to 24.5%	FY26
US Sales	Closer to $1 billion	FY '27
Biosimilars	Launching one biosimilar in the U.S. market	Q2 FY26
Biosimilars R&D Spend	$100 million	Next 3 years